Rhythm Pharmaceuticals In... (RYTM)
NASDAQ: RYTM
· Real-Time Price · USD
99.02
1.79 (1.84%)
At close: Oct 03, 2025, 3:59 PM
1.84% (1D)
| Bid | 96 |
| Market Cap | 6.58B |
| Revenue (ttm) | 156.29M |
| Net Income (ttm) | -183.06M |
| EPS (ttm) | -3.01 |
| PE Ratio (ttm) | -32.9 |
| Forward PE | -51.82 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 105 |
| Volume | 645,480 |
| Avg. Volume (20D) | 718,179 |
| Open | 96.83 |
| Previous Close | 97.23 |
| Day's Range | 96.74 - 102.79 |
| 52-Week Range | 45.91 - 106.52 |
| Beta | 2.24 |
| Ex-Dividend Date | n/a |
About RYTM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RYTM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RYTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsRhythm Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 4, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+36.63%
Rhythm Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
5 months ago
+5.04%
Rhythm Pharmaceuticals shares are trading higher after multiple analysts raised their price targets on the stock.
1 month ago · seekingalpha.com
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call TranscriptRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David...
2 months ago · seekingalpha.com
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity MarketRhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market...
